$16.51
Price
$851M
Market Cap
7.4
P/E Ratio
13.2
Forward P/E
$2.23
EPS (TTM)
—
Dividend Yield
$395M
Cash
$43M
Total Debt
52M
Shares Out
$8.40
$21.03
52-Week Range
Institutional Ownership of THERAVANCE BIOPHARMA INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for THERAVANCE BIOPHARMA INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2022-Q3 | |||||
| SELL | EXIT | — | — | $9.34 | |
| 2022-Q2 | |||||
| SELL | -6.3% | 28.1M | $26M | $9.10 | |
Insider Trading for THERAVANCE BIOPHARMA INC
6 Months Insider Sentiment
Buy $0
Sell $583K
0
Buys
3
Sells
-583K
Net
0
Grants
Largest
$291K
Farnum
$146K
Farnum
$146K
Farnum
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 03, 2025 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | SELL | 7.8K | $18.75 | $146K |
| Dec 03, 2025 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | SELL | 7.8K | $18.75 | $146K |
| Dec 03, 2025 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | SELL | 15.5K | $18.75 | $291K |